January 6, 2025 10:56 AM EST
News Briefing

I-Mab stops work on CD73; Citius to pur­sue ‘strate­gic’ op­tions

ENDPOINTS

Plus, news about Gen­er­al Prox­im­i­ty and PBS Biotech:

I-Mab paus­es CD73 de­vel­op­ment: The com­pa­ny is not mov­ing for­ward with a pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

A service from the Financial Times